In this episode, Associate Blood editor Dr. Selina Luger leads a discussion with Drs. Courtney DiNardo, Eunice Wang, Andrew Wei and Gail Roboz about the advances in treatment options for Acute Myeloid Leukemia (AML). The conversation highlights new combinations like Venetoclax-azacitidine, challenges with differentiation syndrome, and emerging strategies for secondary AML patients. The authors emphasize moving beyond traditional one-size-fits-all treatments to more nuanced, patient-specific care that considers individual genetic profiles and potential complications. These insights provide a comprehensive overview of the latest innovations in AML treatment, offering healthcare professionals critical updates on managing this complex disease. See the full How I Treat series on Acute Myeloid Leukemia in volume 145 issue 12 of Blood journal.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related